Lincoln Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lincoln Pharmaceuticals has informed the stock exchanges that its trading window will be closed starting July 1, 2025, in line with SEBI's insider trading regulations. The window will remain shut until 48 hours after the company declares its unaudited financial results for the quarter ended June 30, 2025 (Q1 FY26). The exact board meeting date to approve these results has not yet been announced but will be communicated later. During this period, directors, senior management, promoters, promoter group members, and their immediate relatives are barred from trading in the company's shares. This is a routine compliance step taken by listed companies ahead of their quarterly earnings announcement.
This is a standard regulatory filing and not a material business event. However, it signals that Q1 FY26 results are likely due in early-to-mid July 2025, which may act as a near-term catalyst for the stock. Shareholders should watch for the upcoming board meeting date and earnings announcement, as the window typically reopens shortly after results are published.